CG Oncology, Inc. (NASDAQ:CGON) Director Leonard E. Post Sells 1,000 Shares

CG Oncology, Inc. (NASDAQ:CGON) Director Leonard E. Post sold 1,000 shares of the business’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $29.66, for a total transaction of $29,660.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Leonard E. Post also recently made the following trade(s):

• On Friday, December 6th, Leonard E. Post sold 1,000 shares of CG Oncology stock. The stock was sold at an average price of $34.54, for a total value of $34,540.00.

CG Oncology Stock Down 2.5 %

CG Oncology stock traded down $0.71 during trading hours on Tuesday, hitting $27.97. 597,149 shares of the company traded hands, compared to its average volume of 703,322. CG Oncology, Inc. has a 1-year low of $25.77 and a 1-year high of $50.23. The firm’s 50-day simple moving average is $32.28 and its two-hundred day simple moving average is $34.25.

CG Oncology (NASDAQ:CGON) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.06. The company had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.30 million. CG Oncology had a negative net margin of 10,642.98% and a negative return on equity of 18.97%. On average, analysts expect that CG Oncology, Inc. will post -1.32 EPS for the current fiscal year.

Institutional Investors Weigh In On CG Oncology

A number of institutional investors have recently bought and sold shares of the business. Amalgamated Bank grew its stake in shares of CG Oncology by 107.6% in the 3rd quarter. Amalgamated Bank now owns 1,621 shares of the company’s stock valued at $61,000 after buying an additional 840 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of CG Oncology during the 3rd quarter valued at about $241,000. Profund Advisors LLC bought a new position in shares of CG Oncology in the 2nd quarter valued at approximately $300,000. HighVista Strategies LLC bought a new stake in CG Oncology during the third quarter worth approximately $594,000. Finally, M&T Bank Corp grew its holdings in CG Oncology by 55.7% during the third quarter. M&T Bank Corp now owns 16,758 shares of the company’s stock valued at $632,000 after purchasing an additional 5,996 shares during the last quarter. 26.56% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. TD Cowen assumed coverage on shares of CG Oncology in a research note on Tuesday, January 7th. They set a “buy” rating on the stock. UBS Group initiated coverage on shares of CG Oncology in a research report on Thursday, October 24th. They set a “buy” rating and a $60.00 price target for the company. Bank of America reaffirmed a “buy” rating and issued a $65.00 target price on shares of CG Oncology in a research report on Tuesday, October 8th. Royal Bank of Canada reissued an “outperform” rating and set a $66.00 price target on shares of CG Oncology in a research report on Friday, December 6th. Finally, HC Wainwright reiterated a “buy” rating and set a $75.00 target price on shares of CG Oncology in a report on Friday. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $63.88.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.